ストックスクリーナーアプリを入手
189.68
0.51%
-0.97
前日終値:
$190.65
開ける：
$189.92
24時間の取引高:
1.50M
Relative Volume:
1.33
時価総額：
$10.70B
収益：
$763.34M
当期純損益:
$51.40M
株価収益率:
208.81
EPS:
0.9084
ネットキャッシュフロー:
$104.46M
1週間 パフォーマンス:
+7.23%
1か月 パフォーマンス:
+4.40%
6か月 パフォーマンス:
+65.92%
1年 パフォーマンス:
+55.88%
1日の値動き範囲:
$186.91
$191.51
1週間の範囲:
$176.22
$192.49
52週間の値動き範囲:
$100.99
$192.49
Repligen Corp Stock (RGEN) Company Profile
Compare RGEN vs ISRG, BDX, RMD, ALC, MDLN
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RGEN
Repligen Corp
|
189.68 | 10.70B | 763.34M | 51.40M | 104.46M | 0.9084 |
ISRG
Intuitive Surgical Inc
|
405.18 | 143.14B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
183.82 | 50.07B | 21.37B | 1.41B | 3.07B | 3.9437 |
RMD
Resmed Inc
|
222.00 | 32.02B | 5.54B | 1.52B | 1.74B | 10.37 |
ALC
Alcon Inc
|
64.47 | 31.16B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
34.70 | 30.44B | 29.14B | 1.07B | 1.05B | 1.1956 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-09-09 | 再開されました | UBS | Buy |
| 2026-07-07 | アップグレード | The Benchmark Company | Hold → Buy |
| 2026-06-02 | 再開されました | Wolfe Research | Outperform |
| 2026-05-15 | 再開されました | RBC Capital Mkts | Outperform |
| 2026-04-17 | 開始されました | Rothschild & Co Redburn | Buy |
| 2025-10-01 | 開始されました | HSBC Securities | Buy |
| 2025-09-22 | アップグレード | Evercore ISI | In-line → Outperform |
| 2025-07-22 | 再開されました | Stephens | Overweight |
| 2025-06-24 | 開始されました | Barclays | Overweight |
| 2025-04-29 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 開始されました | Evercore ISI | In-line |
| 2025-02-10 | 開始されました | TD Cowen | Buy |
| 2024-12-17 | 開始されました | Canaccord Genuity | Hold |
| 2024-11-14 | 開始されました | Wolfe Research | Peer Perform |
| 2024-08-28 | 開始されました | Wells Fargo | Overweight |
| 2024-06-26 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-06-18 | 開始されました | Guggenheim | Neutral |
| 2023-12-04 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2023-07-20 | 開始されました | Wells Fargo | Overweight |
| 2023-07-05 | 再開されました | JP Morgan | Overweight |
| 2023-03-28 | 開始されました | The Benchmark Company | Buy |
| 2022-12-14 | 開始されました | Deutsche Bank | Hold |
| 2022-12-07 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2022-07-20 | 開始されました | UBS | Buy |
| 2021-10-14 | 開始されました | Exane BNP Paribas | Outperform |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2020-08-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-07 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-23 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-11-15 | 開始されました | Stifel | Buy |
| 2019-11-01 | アップグレード | First Analysis Sec | Outperform → Strong Buy |
| 2019-10-15 | 開始されました | SVB Leerink | Outperform |
| 2019-08-28 | 繰り返されました | First Analysis Sec | Outperform |
| 2019-08-23 | 再開されました | Stephens | Overweight |
| 2019-07-22 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2018-12-17 | アップグレード | CL King | Neutral → Buy |
| 2018-11-12 | ダウングレード | CL King | Buy → Neutral |
| 2018-09-26 | 開始されました | H.C. Wainwright | Neutral |
| 2017-12-08 | 開始されました | Citigroup | Buy |
| 2017-12-05 | 開始されました | JP Morgan | Overweight |
| 2017-11-13 | 開始されました | CL King | Buy |
| 2017-10-02 | アップグレード | First Analysis Sec | Equal-Weight → Overweight |
| 2017-07-21 | 開始されました | William Blair | Outperform |
| 2017-02-13 | アップグレード | Piper Jaffray | Neutral → Overweight |
すべてを表示
Repligen Corp (RGEN) 最新ニュース
Form 4 Repligen Corporation For: 26 September By Investing.com - Investing.com India
Repligen CEO Loeillot sells $2.46m in shares - Investing.com
Repligen CEO Loeillot sells $2.46m in shares By Investing.com - Investing.com Australia
Repligen Corp (RGEN) CEO Olivier Loeillot Sells 12,946 Shares - GuruFocus
Repligen (RGEN) CEO sells shares at $190 each after exercising options under a trading plan. - Stock Titan
Repligen Corporation (RGEN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Repligen Corporation (RGEN) stock price, news, quote and history - Yahoo Finance UK
Form 144 REPLIGEN CORP For: 24 September By Investing.com - Investing.com Nigeria
Repligen Corporation (RGEN) Stock Forecasts - Yahoo Finance
Is Repligen Corp (RGEN) Overvalued After 3.3% Rally? GF Value Sa - GuruFocus
Shares valued at $2.46 million are listed for sale by a Repligen (NASDAQ: RGEN) officer and director. - Stock Titan
Repligen Corp Stock Baskets - GuruFocus
Repligen Corp (BSP:R2GE34) Stock Price & 30 Year Financial Data - GuruFocus
Repligen Corporation stock hits 52-week high at 188.95 USD - Investing.com
Repligen Corp (RGEN) CEO Olivier Loeillot Sells 5,426 Shares - GuruFocus
Repligen Corp (RGEN) Stock Up 3.3% but GF Value Says Overvalued -- GF Score: 87/100 - GuruFocus
Repligen (RGEN) CEO sells 5,426 shares under plan - Stock Titan
Biolife Solutions stock hits 52-week high at $38.10 By Investing.com - Investing.com Canada
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290 - Zacks Investment Research
Repligen (NASDAQ: RGEN) insider plans new stock sale after two recent trades - Stock Titan
Repligen Stock Price Forecast. Should You Buy RGEN? - StockInvest.us
Repligen (NASDAQ: RGEN) Director Karen Dawes to Step Down on September 30, 2026 - Kalkine Media
Karen A. Dawes to Retire from Repligen Board Effective Sept 30, 2026 - TradingView
Could Pricing Pressure Change the Repligen (NASDAQ:RGEN) Story? - Kalkine Media
BioLife Solutions merger with Repligen advances as antitrust waiting period ends - Investing.com
BioLife Solutions' HSR Antitrust Waiting Period Ends Ahead of Repligen Merger - Kalkine Media
Repligen at Wells Fargo conference: growth broadens beyond headwinds - Investing.com
REPLIGEN CEO Loeillot Olivier Forfeits 2,842 Shares at $169.61 and Sells 3,035 Shares at $165.90 (NASDAQ: RGEN) - Kalkine Media
3 Reasons to Avoid RGEN and 1 Stock to Buy Instead - Yahoo Finance
Repligen to acquire BioLife for $11.25 cash plus 0.1442 shares per BioLife share; HSR waiting period expired - TradingView
[425] REPLIGEN CORP Business Combination Communication | RGEN SEC FilingForm 425 - Stock Titan
Repligen (RGEN) CEO trades stock in preset plan - Stock Titan
Repligen (NASDAQ: RGEN) Schedules October 5 Vote for BioLife Merger Approval - Kalkine Media
REPLIGEN CORP SEC Filing (Sep 8, 2026) - Stock Titan
ZimVie Inc. When-Issued (ZIMVV) Peer Comparison – Compare with Others - Value Research
Repligen Corp (NASDAQ:RGEN) Combines Strong Growth with a Constructive Technical Setup - ChartMill
Repligen Corporation (RGEN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Repligen (RGEN) holder lines up new sale after $976K trade - Stock Titan
Heska Corporation (HSKA) Peer Comparison – Compare with Others - Value Research
What Repligen (NASDAQ: RGEN) plans to pay for each BioLife share - Stock Titan
Repligen (RGEN) Stock Looks Near Fair Value After Recent Rebound - Yahoo Finance
Repligen Offers Differentiated Solutions as a Leading Bioprocessing Supplier - Morningstar
Codex DNA Inc (DNAY) Peer Comparison – Compare with Others - Value Research
Repligen (NASDAQ: RGEN) awards 2,466 stock units to its chief accounting officer - Stock Titan
A Look at Repligen Corp (RGEN) After 6.1% Decline -- GF Value $1 - GuruFocus
Apria Inc. (APR) Peer Comparison – Compare with Others - Value Research
Repligen Shares Slide as Market Weighs BioLife Deal Dilution and Execution Risk - Quiver Quantitative
Acutus Medical Inc (AFIB) Peer Comparison – Compare with Others - Value Research
Repligen Corporation (RGEN) Stock Price, Chart, News & Analysis - securities.io
Repligen Corporation (RGEN) Peer Comparison – Compare with Others - Value Research
Repligen Corp (RGEN) Shares Fall 3.2% -- What GF Score of 87 Tel - GuruFocus
Repligen Corp (RGEN) 財務データ
収益
当期純利益
現金流量
EPS
Repligen Corp (RGEN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Loeillot Olivier | Chief Executive Officer |
Sep 24 '26 |
Sale |
190.00 |
12,946 |
2,459,740 |
48,369 |
0.00%
0.47%
大文字化:
|
ボリューム (24 時間):